There is a strong demand for the identification of new biomarkers in colorectal cancer (CRC) diagnosis. Among all liquid biopsy analysts, cell-free circulating DNA (cfDNA) is probably the most promising tool with respect to the identification of minimal residual diseases, assessment of treatment response and prognosis, and identification of resistance mechanisms. Circulating cell-free tumor DNA (ctDNA) maintains the same genomic signatures that are present in the matching tumor tissue allowing for the quantitative and qualitative evaluation of mutation burdens in body fluids. Thus, ctDNA-based research represents a non-invasive method for cancer detection. Among the numerous possible applications, the diagnostic, predictive, and/or prognostic utility of ctDNA in CRC has attracted intense research during the last few years. In the present review, we will describe the different aspects related to cfDNA research and evidence from studies supporting its potential use in CRC diagnoses and the improvement of therapy efficacy. We believe that ctDNA-based research should be considered as key towards the introduction of personalized medicine and patient benefits.

• Klíčová slova
• cell-free DNA, colorectal cancer, liquid biopsy,
• MeSH
• cirkulující nádorová DNA analýza   krev   genetika   MeSH
• kolon patologie   MeSH
• kolorektální nádory krev   diagnóza   genetika   patologie   MeSH
• lidé MeSH
• nádorové biomarkery analýza   krev   genetika   MeSH
• prognóza MeSH
• rektum patologie   MeSH
• tekutá biopsie metody   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• systematický přehled MeSH
• Názvy látek
• cirkulující nádorová DNA MeSH
• nádorové biomarkery MeSH